Overcoming Downstream Bottlenecks in the Upscaling Process
Posted on November 22, 2018
Over the past decade, the demand for biological therapeutics, particularly monoclonal antibodies, has increased markedly. With annual demands for therapeutic antibodies reaching several metric tons, batches >100 kg of protein are becoming more common1. Technological advancement in cell culture ha...
To read the full article and other articles in this issue, please register for a free account or log in.
Subscribe to our FREE newsletter